BridgeMD
New treatment option for Asthma (Diagnosis)
Official title Can Astaxanthin Help Manage Asthma in POlluted Areas?
ClinicalTrials.gov ID: NCT07507682
What this study is testing
- What it's testing
- This study will test whether astaxanthin, a naturally occurring antioxidant supplement, can improve lung function, reduce airway inflammation, and improve asthma control in adults with mild-to-moderate asthma. Participants will receive astaxanthin and placebo in random order in a double-blind crossover design.
- Time commitment: about 4 weeks
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Adults 18+ y
- Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:
- A physician diagnosed asthma condition consistent with BTS/NICE/SIGN (2024)
- Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment
- No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks (those with suspected Asthma will be invited to a...
You likely can't join if
- Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased...
- Respiratory tract infection within the preceding 4 weeks
- Pregnant or lactating individuals
- Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases
- Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism
- Known allergy or hypersensitivity to ASTX or any components of the study supplement
See the full eligibility criteria
- Adults 18+ y
- Confirmed clinical diagnosis of mild-to-moderate asthma, defined as:
- A physician diagnosed asthma condition consistent with BTS/NICE/SIGN (2024)
- Asthma managed at GINA (2024) step 1-3 therapy level, with stable maintenance treatment for ≥4 weeks prior to enrolment
- No asthma exacerbation requiring systemic corticosteroids within the preceding 6-8 weeks (those with suspected Asthma will be invited to a familiarisation and eligibility session where they will have clinical...
- Ability to demonstrate acceptable and repeatable spirometry in accordance with ATS/ERS standards
- Willing to refrain from antioxidant and anti-inflammatory supplementation (e.g. Omega-3, turmeric, NSAID supplements) for the duration of the study
- Not consuming high dietary ASTX sources (e.g., frequent salmonid or crustacean intake), assessed at screening
- non-smoking and non-vaping
- Able and willing to take daily study capsules and attend all required visits
- Able and willing to complete home monitoring, including peak flow, air-quality monitoring, and questionnaires
- Able to provide written informed consent
- Current smokers or vapers which is associated with chronic airway remodelling, reduce hyperresponsiveness to bronchodilators, and increased neutrophilic inflammation, which can obscure the true effects of asthma-target...
- Respiratory tract infection within the preceding 4 weeks
- Pregnant or lactating individuals
- Presence of significant co-morbidities, including CVD or autoimmune or systemic inflammatory diseases
- Renal or gastrointestinal disorders that may affect astaxanthin absorption and metabolism
- Known allergy or hypersensitivity to ASTX or any components of the study supplement
- History of current evidence of alcohol or substance abuse
- Participation in another treatment drug or supplement study within the preceding 3 months
- Use of medicines with a narrow therapeutic index where supplement interactions may pose risk (e.g., ciclosporin/tacrolimus, warfarin), assessed by investigator
- Other significant chronic respiratory disease (e.g., COPD, bronchiectasis)
The study team makes the final eligibility decision.
Where it's taking place
- London, Barnet, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 4 weeks per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include London, Barnet, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.